2 year study of AxSpA pts in clinical remission who tapered TNFi. ⭐️52% successfully tapered to either 2/3, 1/2 or 1/3 dose ⭐️Baseline physician global score independent predictor of successful tapering Abs#364 #ACR21 @RheumNow https://t.co/9Kti5JGMYr https://t.co/y1Uj2dTABC

• Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Rou…

@ericdeinmd @RheumNow *TICOSPA IMO, more an issue of poor tools for activity monitoring and insufficiently diverse toolbox. Works in RA as lots of choices and good activity measures. Until AxSpa has those, don’t see how we hope to meet “tight control”.

Irish registry of AS pts included 76 women who were pregnant ⭐️58% uncomplicated, 41.9% complicated, 11% multiple complications ⭐️frequency of miscarriage ⬆️ ⭐️complications included C-section, preterm, NICU admission #ACR21 @RheumNow Abs#369 https://t.co/90dolEeTIw

Self-monitoring app for AxSpA pts ⭐️adherence over 6 months poor 😔 ⭐️high disease activity and older age related to ⬆️frequency of reporting Abs#373 #ACR21 @RheumNow

#ACR21 Year in Review: TICOPSA - tight control treat to target in AxSpa does not meet primary endpoint, but favorable secondary outcomes. Was the control group at academic center already receiving good tight control? @Rheumnow

#ACR21 #ACRbest @RheumNow Abst#0366 by Garrido-Cumbrera et al. looked at shows that three out of four European axSpA patients have difficulty in finding a job.

T2T in AxSpA? ASDAS-qCRP & ASDAS-CRP showed an almost perfect agreement w/ regard to dz activity categories (96%.) Quick ASDAS-qCRP can be used in real time to make clinical decisions. Abs 0374 #ACR21 #RheumNow @RheumNow https://t.co/opOyedQUaZ https://t.co/aeUEsW9HsX

• Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Qu…

Biologic dose tapering in #axialspondyloarthritis in 52% of patients if criteria are met (BASDAI)< 40, physician global score< 40 and no signs of disease activity the previous year, escalation to previous dose if there is a flare @RheumNow #ACR21 Abst#0364 https://t.co/4GntJ6jS11

• Dose Tapering of TNF Inhibitors in Patients with Axial Spondyloarthritis in Rou…

Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

• Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloar…

#ACR21 @RheumNow Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017 ⭐️Higher spinal disease: Male gender; longer disease duration; smoking ⭐️🔼Disease progression 🔼CRP levels ⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz

AxSpA pts share a gut microbiome signature with Crohn's disease and anterior uveitis pts ⬇️Blautia ⬆️Veillonella and Lactobacillus ⭐️SpA pts uniquely enriched in Collinsella Abs#0062 #ACR21 @RheumNow #ACRBest https://t.co/sdlHxNbhr8 https://t.co/r8eG9c9vwa

• Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Mi…

Early axSpA DESIR: higher dz activity & worse function independently assoc'd w/ ^ hazard of Work Disability vs SES. Dz severity strong predictor of adverse work outcome despite advanced therapeutic strategies in axSpA. Abs 0381 #ACR21 #RheumNow @RheumNow https://t.co/Lc3yUgXvw6

• How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Ax…

Is it time to consider targeting gut microbiome for treatment of AS? Large study identified: ⭐️Ruminococcus torques associated with FUT2 gene influences risk of developing AS Abs#0068 https://t.co/E1hL18KZbQ #ACR21 #ACRBest @RheumNow

• Gut Bacteria Causing Ankylosing Spondylitis Identified Through Mendelian Random…

Possible disease activity biomarkers in axSpA? Neutrophil lymphocyte ratio (NLR) & platelet lymphocyte ratio (PLR) along w/ PROs may be helpful to measure dz activity clinically. More studies needed for proof of concept. Abs 0384 #ACR21 #RheumNow @RheumNow https://t.co/ZXyQHNzqz7 https://t.co/va5fBR9Gnk

• A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in …